Bank Of Montreal Nektar Therapeutics Transaction History

Bank Of Montreal

$214 Billion
Q3 2024

A detailed history of Bank Of Montreal transactions in Nektar Therapeutics stock. As of the latest transaction made, Bank Of Montreal holds 54,502 shares of NKTR stock, worth $58,317. This represents 0.0% of its overall portfolio holdings.

Number of Shares

54,502

Previous 54,500 -0.0%

Holding current value

$58,317

Previous $67,000 4.48%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$1.11 - $1.48 $2 - $2	2 Added 0.0%	54,502 $70,000
Q1 2024 May 13, 2024	SELL	$0.49 - $0.96 $51,009 - $99,936	-104,100 Reduced 65.64%	54,500 $50,000
Q4 2023 Feb 08, 2024	BUY	$0.42 - $0.57 $60,939 - $82,703	145,093 Added 1074.21%	158,600 $88,000
Q2 2023 Aug 02, 2023	SELL	$0.53 - $1.03 $11,038 - $21,451	-20,827 Reduced 60.66%	13,507 $7,000
Q1 2023 Jun 13, 2024	SELL	$0.64 - $3.15 $9,471 - $46,616	-14,799 Reduced 27.15%	39,701 $27,000
Q4 2022 Feb 01, 2023	SELL	$2.03 - $4.28 $32,985 - $69,545	-16,249 Reduced 32.12%	34,334 $77,000
Q3 2022 Nov 10, 2022	SELL	$3.04 - $5.14 $707,365 - $1.2 Million	-232,686 Reduced 82.14%	50,583 $168,000
Q2 2022 Aug 11, 2022	BUY	$3.17 - $6.17 $679,676 - $1.32 Million	214,409 Added 311.37%	283,269 $1.17 Million
Q1 2022 May 12, 2022	SELL	$4.16 - $13.72 $23,641 - $77,970	-5,683 Reduced 7.62%	68,860 $384,000
Q4 2021 Feb 11, 2022	BUY	$10.83 - $18.41 $443,510 - $753,926	40,952 Added 121.91%	74,543 $1.05 Million
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $21,839 - $31,481	-1,671 Reduced 4.74%	33,591 $632,000
Q2 2021 Aug 12, 2021	BUY	$16.52 - $20.4 $582,528 - $719,344	35,262 New	35,262 $626,000

Others Institutions Holding NKTR

# of Institutions

147

Shares Held

139M

Call Options Held

32.6K

Put Options Held

14.1K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account